|MNC (JVs and subsidiaries)|
|Headquarters||Hinjwadi, Pune, India|
Satish Mehta CEO
|Products||tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products|
Number of employees
Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company. The company's legal products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
- Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
- Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
- Oncology injectable facility at Hinjawadi
- Solid Orals facilities at Jammu and Bhosari
- API facility at Kurkumbh- USFDA approved
- Biotech facility at Hinjawadi
- R&D center and upcoming plant at Ahmedabad
USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.
There have been many cases of recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus Anthracis, Penicillium Chrysogenum & E coli in some samples. Teva recalled several batches of two products due to white tablets showing presence of Yersinia Pestis in 2011.
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility (which all of the public knows is just lofty words thinly disguissed as altruistic concern)it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version. The monthly doses priced at around $30 million are expected to be raised significantly for lesser access to cancer therapy.
- "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.
- "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.